Clin2
NCT04728516Possibly a fitRecruiting

Eradication treatment versus acid pills to prevent GI bleeding

Acute Coronary SyndromeHelicobacter Pylori Infection

Treatments studied

Part of Heart & circulation clinical trials.

This trial compares a “dual eradication therapy” (to get rid of H. pylori in the stomach) versus usual acid-reducing pills (PPIs) to lower the risk of gastrointestinal bleeding in people with recent heart artery disease treated with a stent. It may help by reducing stomach infection-related bleeding while you continue needed heart medicines.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
2,600 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have had ACS (acute coronary syndrome) treated with a PCI stent, and you’ve been on dual antiplatelet therapy for at least 6 months
  • Your stomach test shows a positive H. pylori (H. pylori infection)
  • You are age 18 or older and can sign consent (or a legal representative can)
  • No prior history of stomach ulcer bleeding
  • You are not taking long-term acid blockers like PPIs or H2 blockers in the recent past
  • You have no major bleeding risks or severe lab/organ issues, and you’re able to describe symptoms

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07537634Recruiting· Phase 4
New stomach acid medicine versus standard treatment for H. pylori infection

This trial compares two different antibiotic combinations to treat H. pylori, a common stomach bacteria that causes indigestion and ulcers. One uses a newer acid-blocking medicine (vonoprazan) and the other uses a standard one (esomeprazole), both paired with antibiotics.

Dhaka
NCT06929962Recruiting· Phase 4
VA dual sequential therapy for H. pylori gastritis

This trial tests a new two-step antibiotic treatment for adults with chronic gastritis caused by H. pylori bacteria. If you have not been treated for H. pylori before and are between 18 and 70, you may be able to join.

Nanjing, Jiangsu
NCT06959368Recruiting· Phase 4
New H. pylori treatment vs standard triple therapy

This trial compares a newer drug (vonoprazan) plus antibiotics to the standard triple therapy for eradicating H. pylori infection in the stomach. It may be a good option if you have stomach symptoms like indigestion, acid reflux, or a non-bleeding ulcer and have not been treated for H. pylori before.

Hyderabad, Telangana
NCT04416581Recruiting· Phase 4
Compare two stomach-protecting medicines to prevent bleeding

This trial compares a potassium-competitive acid blocker to a proton pump inhibitor to help prevent stomach or intestinal bleeding in people at high risk who take blood-thinning medicines. It may help reduce dangerous GI bleeding while you stay on heart/stroke medicines.

Anyang
NCT07242456Recruiting· Phase 2/Phase 3
Comparing two treatments for H. pylori infection

This study tests two different combinations of medications to treat H. pylori, a stomach bacteria that can cause ulcers. You would take one of the two combinations for a short time to see which works better at getting rid of the infection.

Hangzhou, Zhejiang
NCT07439445Recruiting
Simplified treatment for H. pylori guided by a stool test

This trial tests a simpler two-drug treatment for H. pylori infection, chosen based on a stool test that checks if the bacteria are resistant to clarithromycin. It may help people who have not been treated before avoid unnecessary antibiotics.

Beijing, Beijing Municipality

Hear when a new Acute Coronary Syndrome trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.